CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CU6 - CLARITY PHARMACEUTICALS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.61

17 Dec
2024

0.030

OPEN

$4.56

0.66%

HIGH

$4.71

1,433,553

LOW

$4.45

TARGET
$10.00 116.9% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CU6: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 15.5 - 21.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-15.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx46.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-43.2 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-39.29 %
Return on Invested Capital xxxxxxxxxxxxxxx-39.29 %
Return on Assets xxxxxxxxxxxxxxx-36.56 %
Return on Equity xxxxxxxxxxxxxxx-39.29 %
Return on Total Capital xxxxxxxxxxxxxxx-52.26 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-43.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx137 M
Price To Book Value xxxxxxxxxxxxxxx11.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx56 M
Research & Development xxxxxxxxxxxxxxx46 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

29/11/2024

1

Speculative Buy

$10.00

116.92%

The Clarity Pharmaceuticals' AGM provided various updates including the start of recruitment for the Co-PSMA trial, notes Bell Potter. Data from previous trials strongly suggested 64Cu SAR-bisPSMA will outperform 68Ga-PSMA11 in the detection of early-stage tumours.

Management also noted the last patient in the Disco trial evaluating the 64Cu SARTATE asset for the imaging of Neuroendocrine tumours has completed his/her final assessment. Next step is release of final results in the 1H of 2025, highlights the broker.

The Speculative Buy rating is maintained with $10 target price.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -21.60 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

13/12/2024

1

Overweight

$8.48

83.95%

Clarity Pharmaceuticals is progressing with its Co-PSMA trial to evaluate 64Cu-SAR-bisPSMA against 68Ga-PSMA-11 in detecting biochemical recurrence of prostate cancer, highlights Wilsons .

The broker highlights revised timing assumptions for 64Cu-SAR-bisPSMA which defers the analyst's revenue forecast to 2027, while maintaining the peak sales estimate of US$950m.

Wilsons feels the recent share price correction may reflect perceptions of market challenges for new entrants, though Clarity’s differentiated clinical benefits are seen as promising.

Overweight rating maintained. Target slips to $8.40 from $8.48.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents.
Access Extra Coverage Research History >

CU6 STOCK CHART

FNArena News on CU6

1
Australian Broker Call *Extra* Edition – Dec 16, 2024

Dec 16 2024 - Daily Market Reports
2
In Brief: Pro Medicus, Superloop, Clarity & More

Dec 13 2024 - Weekly Reports
3
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View
4
Australian Broker Call *Extra* Edition – Nov 06, 2024

Nov 06 2024 - Daily Market Reports
5
Next Week At A Glance – 21-25 Oct 2024

Oct 18 2024 - Weekly Reports

Latest Medical Equipment & Devices News

1
Diagnostic Imaging Radiates Opportunity

10:00 AM - Small Caps
2
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
3
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
4
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
5
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
6
ResMed Silences The Doubters

Apr 29 2024 - Australia
7
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
8
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
9
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
10
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View